Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Fecal Occult Testing Market by Product (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test) and by End User (Hospitals, Clinical Diagnostic Laboratories, Physicians' Office Laboratories): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03490

Pages: NA

Charts: NA

Tables: NA

Fecal occult test is a medical test used to check stool samples for hidden or occult blood. The presence of occult blood indicates the presence of colon cancer or polyps in the colon or rectum, ulcers, anal fissures, Crohns disease, and many more conditions. The fecal occult test is used in clinical screening to detect colon cancer.

The major factors that contribute to the growth of the fecal occult testing market include increasing prevalence of rectal & colon cancer, initiatives taken by the government such as organizing colorectal cancer check-ups, improved medical infrastructure, and adoption of advanced fecal occult testing. However, factors such as less awareness about the test and high costs may restrain the market growth. The development of direct-to-consumer laboratory testing and availability of fecal occult immunological test devices in online stores will further provide lucrative market growth opportunities during the forecast period.

The fecal occult testing market is segmented on the basis of product, end user, and region. On the basis of product, the market is segmented into guaiac FOB stool test, immuno-FOB agglutination test, lateral flow immuno-FOB test, and immuno-FOB ELISA test. According to end user, the market is divided into hospitals, clinical diagnostic laboratories, and physicians' office laboratories. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Quidel Corporation, EIKEN CHEMICAL CO., LTD., Epigenomics AG, Beckman Coulter, Inc., Abbott Laboratories, Biohit Oyj., Polymedco CDP, LLC, Quest Diagnostics Incorporated, Randox Laboratories Ltd., and EDP Biotech.

Key Benefits

  • The study provides an in-depth analysis of the global fecal occult testing market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global fecal occult testing market which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the global fecal occult testing market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global fecal occult testing market.

 Key Market Segments

  • By Product
    • Guaiac FOB Stool Test
    • Immuno-FOB Agglutination Test
    • Lateral Flow Immuno-FOB Test
    • Immuno-FOB ELISA Test
  • By End User
    • Hospitals
    • Clinical Diagnostic Laboratories
    • Physicians' Office Laboratories
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • EDP Biotech
  • Abbott Laboratories
  • Beckman Coulter Inc.
  • EIKEN CHEMICAL CO.LTD.
  • Randox Laboratories Ltd.
  • Epigenomics AG
  • Polymedco CDP LLC
  • Quest Diagnostics Incorporated
  • Biohit Oyj.
  • Quidel Corporation

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: FECAL OCCULT TESTING MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Guaiac FOB Stool Test

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immuno-FOB Agglutination Test

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Lateral Flow Immuno-FOB Test

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Immuno-FOB ELISA Test

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: FECAL OCCULT TESTING MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinical Diagnostic Laboratories

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Physicians' Office Laboratories

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: FECAL OCCULT TESTING MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Fecal Occult Testing Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Fecal Occult Testing Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Fecal Occult Testing Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Fecal Occult Testing Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Fecal Occult Testing Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Fecal Occult Testing Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Fecal Occult Testing Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Fecal Occult Testing Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Fecal Occult Testing Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Fecal Occult Testing Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Fecal Occult Testing Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Fecal Occult Testing Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Fecal Occult Testing Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Fecal Occult Testing Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Fecal Occult Testing Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Fecal Occult Testing Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Fecal Occult Testing Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Fecal Occult Testing Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Fecal Occult Testing Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Fecal Occult Testing Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Fecal Occult Testing Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Fecal Occult Testing Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Fecal Occult Testing Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Fecal Occult Testing Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Fecal Occult Testing Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Quidel Corporation

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. EIKEN CHEMICAL CO.LTD.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Epigenomics AG

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Beckman Coulter Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Abbott Laboratories

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Biohit Oyj.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Polymedco CDP LLC

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Quest Diagnostics Incorporated

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Randox Laboratories Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. EDP Biotech

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL FECAL OCCULT TESTING MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL FECAL OCCULT TESTING MARKET FOR GUAIAC FOB STOOL TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL FECAL OCCULT TESTING MARKET FOR IMMUNO-FOB AGGLUTINATION TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL FECAL OCCULT TESTING MARKET FOR LATERAL FLOW IMMUNO-FOB TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL FECAL OCCULT TESTING MARKET FOR IMMUNO-FOB ELISA TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL FECAL OCCULT TESTING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL FECAL OCCULT TESTING MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL FECAL OCCULT TESTING MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL FECAL OCCULT TESTING MARKET FOR PHYSICIANS' OFFICE LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL FECAL OCCULT TESTING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA FECAL OCCULT TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. U.S. FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 15. U.S. FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. CANADA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 17. CANADA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE FECAL OCCULT TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. ITALY FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. ITALY FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. UK FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. UK FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC FECAL OCCULT TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. CHINA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. CHINA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. INDIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 45. INDIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA FECAL OCCULT TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. UAE FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. UAE FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA FECAL OCCULT TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA FECAL OCCULT TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. QUIDEL CORPORATION: KEY EXECUTIVES
  • TABLE 74. QUIDEL CORPORATION: COMPANY SNAPSHOT
  • TABLE 75. QUIDEL CORPORATION: OPERATING SEGMENTS
  • TABLE 76. QUIDEL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 77. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. EIKEN CHEMICAL CO.LTD.: KEY EXECUTIVES
  • TABLE 79. EIKEN CHEMICAL CO.LTD.: COMPANY SNAPSHOT
  • TABLE 80. EIKEN CHEMICAL CO.LTD.: OPERATING SEGMENTS
  • TABLE 81. EIKEN CHEMICAL CO.LTD.: PRODUCT PORTFOLIO
  • TABLE 82. EIKEN CHEMICAL CO.LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. EPIGENOMICS AG: KEY EXECUTIVES
  • TABLE 84. EPIGENOMICS AG: COMPANY SNAPSHOT
  • TABLE 85. EPIGENOMICS AG: OPERATING SEGMENTS
  • TABLE 86. EPIGENOMICS AG: PRODUCT PORTFOLIO
  • TABLE 87. EPIGENOMICS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. BECKMAN COULTER INC.: KEY EXECUTIVES
  • TABLE 89. BECKMAN COULTER INC.: COMPANY SNAPSHOT
  • TABLE 90. BECKMAN COULTER INC.: OPERATING SEGMENTS
  • TABLE 91. BECKMAN COULTER INC.: PRODUCT PORTFOLIO
  • TABLE 92. BECKMAN COULTER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 95. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 97. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. BIOHIT OYJ.: KEY EXECUTIVES
  • TABLE 99. BIOHIT OYJ.: COMPANY SNAPSHOT
  • TABLE 100. BIOHIT OYJ.: OPERATING SEGMENTS
  • TABLE 101. BIOHIT OYJ.: PRODUCT PORTFOLIO
  • TABLE 102. BIOHIT OYJ.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. POLYMEDCO CDP LLC: KEY EXECUTIVES
  • TABLE 104. POLYMEDCO CDP LLC: COMPANY SNAPSHOT
  • TABLE 105. POLYMEDCO CDP LLC: OPERATING SEGMENTS
  • TABLE 106. POLYMEDCO CDP LLC: PRODUCT PORTFOLIO
  • TABLE 107. POLYMEDCO CDP LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. QUEST DIAGNOSTICS INCORPORATED: KEY EXECUTIVES
  • TABLE 109. QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 110. QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS
  • TABLE 111. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 112. QUEST DIAGNOSTICS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. RANDOX LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 114. RANDOX LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 115. RANDOX LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 116. RANDOX LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 117. RANDOX LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. EDP BIOTECH: KEY EXECUTIVES
  • TABLE 119. EDP BIOTECH: COMPANY SNAPSHOT
  • TABLE 120. EDP BIOTECH: OPERATING SEGMENTS
  • TABLE 121. EDP BIOTECH: PRODUCT PORTFOLIO
  • TABLE 122. EDP BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL FECAL OCCULT TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL FECAL OCCULT TESTING MARKET
  • FIGURE 3. SEGMENTATION FECAL OCCULT TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN FECAL OCCULT TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALFECAL OCCULT TESTING MARKET
  • FIGURE 11. FECAL OCCULT TESTING MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. FECAL OCCULT TESTING MARKET FOR GUAIAC FOB STOOL TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. FECAL OCCULT TESTING MARKET FOR IMMUNO-FOB AGGLUTINATION TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. FECAL OCCULT TESTING MARKET FOR LATERAL FLOW IMMUNO-FOB TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. FECAL OCCULT TESTING MARKET FOR IMMUNO-FOB ELISA TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. FECAL OCCULT TESTING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. FECAL OCCULT TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. FECAL OCCULT TESTING MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. FECAL OCCULT TESTING MARKET FOR PHYSICIANS' OFFICE LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: FECAL OCCULT TESTING MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. QUIDEL CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. QUIDEL CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. QUIDEL CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. EIKEN CHEMICAL CO.LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. EIKEN CHEMICAL CO.LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. EIKEN CHEMICAL CO.LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. EPIGENOMICS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. EPIGENOMICS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. EPIGENOMICS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. BECKMAN COULTER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. BECKMAN COULTER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. BECKMAN COULTER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. BIOHIT OYJ.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. BIOHIT OYJ.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. BIOHIT OYJ.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. POLYMEDCO CDP LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. POLYMEDCO CDP LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. POLYMEDCO CDP LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. QUEST DIAGNOSTICS INCORPORATED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. RANDOX LABORATORIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. RANDOX LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. RANDOX LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. EDP BIOTECH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. EDP BIOTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. EDP BIOTECH: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Fecal Occult Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved